Johnson & Johnson’s SPRAVATO, which is already on track to become a blockbuster drug, has received a significant boost with the FDA’s approval for its use as a standalone treatment for major depressive disorder (MDD). Initially approved in 2019, SPRAVATO was authorized for use alongside an oral antidepressant in patients who did not respond to other antidepressant treatments.
SPRAVATO functions as a non-selective, non-competitive antagonist of the NMDA receptor, impacting glutamate pathways in the brain. While its precise mechanism of antidepressant action is not fully understood, it has been shown to have an effect. In July 2024, Johnson & Johnson filed a ...
